UNLABELLED: Temozolomide a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas; its efficacy has been demonstrated in both pre-clinical and phase I and II studies. The goal of this study is to determine the activity and safety of temozolomide in improving overall survival (OS), progression-free survival (PFS) and health-related quality of life (HQL) in patient with malignant gliomas. Forty-two patients with newly diagnosed glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma were studied. The mean follow-up period was 12 months. The overall response rate (only responsive patient) for all histological groups was 40%, 10 patients (24%) showed a stabilization of disease. The median PFS and OS was respectively 8.35 and 14.1 months: time to progression was 34 week ranging from 21 to 47. In all patients, treatment with temozolomide was associated with improvement of performance status including the patient showing disease progression: Karnofski score improved in all patients by a minimum of 10, with a median of 20 at 6 months. No patient stopped the treatment due to side-effects, no major adverse events were recorded. CONCLUSION: Temozolomide appears to be an ideal, first-line, single-agent, with a safe profile and demonstrated HQL benefits in patients with high-grade gliomas.
UNLABELLED: Temozolomide a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas; its efficacy has been demonstrated in both pre-clinical and phase I and II studies. The goal of this study is to determine the activity and safety of temozolomide in improving overall survival (OS), progression-free survival (PFS) and health-related quality of life (HQL) in patient with malignant gliomas. Forty-two patients with newly diagnosed glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma were studied. The mean follow-up period was 12 months. The overall response rate (only responsive patient) for all histological groups was 40%, 10 patients (24%) showed a stabilization of disease. The median PFS and OS was respectively 8.35 and 14.1 months: time to progression was 34 week ranging from 21 to 47. In all patients, treatment with temozolomide was associated with improvement of performance status including the patient showing disease progression: Karnofski score improved in all patients by a minimum of 10, with a median of 20 at 6 months. No patient stopped the treatment due to side-effects, no major adverse events were recorded. CONCLUSION:Temozolomide appears to be an ideal, first-line, single-agent, with a safe profile and demonstrated HQL benefits in patients with high-grade gliomas.
Authors: C Christodoulou; D Bafaloukos; P Kosmidis; E Samantas; A Bamias; P Papakostas; A Karabelis; C Bacoyiannis; D V Skarlos Journal: Ann Oncol Date: 2001-02 Impact factor: 32.976
Authors: M Brada; K Hoang-Xuan; R Rampling; P Y Dietrich; L Y Dirix; D Macdonald; J J Heimans; B A Zonnenberg; J M Bravo-Marques; R Henriksson; R Stupp; N Yue; J Bruner; M Dugan; S Rao; S Zaknoen Journal: Ann Oncol Date: 2001-02 Impact factor: 32.976
Authors: M J van den Bent; F Keime-Guibert; A A Brandes; M J Taphoorn; J M Kros; F A Eskens; A F Carpentier Journal: Neurology Date: 2001-07-24 Impact factor: 9.910
Authors: C Marzolini; L A Decosterd; F Shen; M Gander; S Leyvraz; J Bauer; T Buclin; J Biollaz; F Lejeune Journal: Cancer Chemother Pharmacol Date: 1998 Impact factor: 3.333
Authors: Marco Hassler; Michael Micksche; Günther Stockhammer; Josef Pichler; Franz Payer; Brigitte Abuja; Robert Deinsberger; Christine Marosi Journal: Wien Klin Wochenschr Date: 2006-05 Impact factor: 1.704
Authors: Young-Hoon Kim; Chul-Kee Park; Won Ho Cho; In Ah Kim; Seyoung Moon; Gheeyoung Choe; Sung-Hye Park; Il Han Kim; Dong Gyu Kim; Hee-Won Jung; Min Mi Lee; So Hyun Bae; Seung Heon Cha; Chae-Yong Kim Journal: J Neurooncol Date: 2010-09-24 Impact factor: 4.130
Authors: Katherine E Warren; Sri Gururangan; J Russell Geyer; Roger E McLendon; Tina Young Poussaint; Dana Wallace; Frank M Balis; Stacey L Berg; Roger J Packer; Stewart Goldman; Jane E Minturn; Ian F Pollack; James M Boyett; Larry E Kun Journal: J Neurooncol Date: 2011-10-04 Impact factor: 4.130
Authors: Oliver Grauer; Christina Pascher; Christian Hartmann; Florian Zeman; Michael Weller; Martin Proescholdt; Alexander Brawanski; Thorsten Pietsch; Wolfgang Wick; Ulrich Bogdahn; Peter Hau Journal: J Neurooncol Date: 2011-03-04 Impact factor: 4.130
Authors: Lauren E Abrey; Barrett H Childs; Nina Paleologos; Lynne Kaminer; Steven Rosenfeld; Donna Salzman; Jonathan L Finlay; Sharon Gardner; Kendra Peterson; Wendy Hu; Lode Swinnen; Robert Bayer; Peter Forsyth; Douglas Stewart; Anne M Smith; David R Macdonald; Susan Weaver; David A Ramsay; Stephen D Nimer; Lisa M DeAngelis; J Gregory Cairncross Journal: Neuro Oncol Date: 2006-03-08 Impact factor: 12.300